<DOC>
	<DOCNO>NCT01080027</DOCNO>
	<brief_summary>The rationale study assess safety profile , efficacy adherence Rebif® New Formulation real life setting multinational approach , well impact improve formulation ( regards adverse event [ AEs ] ) subject ' adherence .</brief_summary>
	<brief_title>Safety , Tolerability Adherence With Rebif® New Formulation Real Life Settings ( STAR )</brief_title>
	<detailed_description>This international , multicentric , prospective , observational study conduct assess safety profile , efficacy adherence Rebif® New Formulation real life setting subject relapse remit multiple sclerosis ( RRMS ) , well impact improve formulation ( regards adverse event [ AEs ] ) subject ' adherence . Three hundred fifty subject approximately 80 site across seven country enrol study . Subjects treat IFN beta-1a ( Rebif® New Formulation ) real life setting accord clinical paraclinical course laboratory finding routinely evaluate physician . Data related AEs ; subject ' adherence treatment , reason treatment discontinuation ; number reason miss injection ; clinical paraclinical data efficacy regard relapse capture . Data report prospectively throughout duration study ( 12 month ) two visit ( month 6 month 12 ) follow initial visit ; baseline , data record retrospectively subject ' medical file . All data evaluate descriptively . OBJECTIVES Primary objective - To assess local tolerability Rebif® New Formulation real life setting multinational approach . Secondary objective - To assess safety profile , subject ' adherence efficacy Rebif® New Formulation</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Subjects diagnosis RRMS accord Mc Donald criterion ( 2005 ) 18 60 year age Expanded Disability Status Scale ( EDSS ) &lt; 6 Naïve subject subject treat Rebif® New Formulation 6 week prior enrollment Subjects give write informed consent participate study Primary progressive secondary progressive MS Subjects previously administer IFN beta1a ( include Rebif® ) IFN beta1b glatiramer acetate immunomodulatory immunosuppressive agent MS therapy past exception Rebif® New Formulation 6 week prior enrollment Subjects receive oral systemic corticosteroid Adrenocorticotrophic hormone within 30 day visit 1 ( prior enrolment ) History chronic pain syndrome Known allergy IFN excipients Serious acute heart disease uncontrolled cardiac dysrhythmias , uncontrolled angina pectoris , cardiomyopathy , uncontrolled congestive heart failure Inadequate liver function , define alanine aminotransferase ( ALT ) &gt; 3 x upper limit normal ( ULN ) , alkaline phosphatase &gt; 2 x ULN , total bilirubin &gt; 2 x ULN associate elevation ALT alkaline phosphatase Inadequate bone marrow reserve , define white blood cell count le 0.5 x low limit normal Current past ( within last 2 year ) history alcohol drug abuse Contraindications IFN beta1a</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Relapsing remit</keyword>
	<keyword>Rebif</keyword>
</DOC>